Global Clinical Practice in Transitioning Protein Substitutes for Children with Phenylketonuria
Nutrients · 2025
DOI: 10.3390/nu17162650 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Ozlem Yilmaz Nas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Birmingham Women's and Children's Hospital, Birmingham B4 6NH, UK. Hauptthemen laut MEDLINE: Phenylketonurias, Infant Formula, Dietary Proteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Protein substitutes are essential in the dietary management of phenylketonuria (PKU). Transition from first-stage phenylalanine (Phe)-free infant formula to second- and third-stage protein substitutes is carefully managed to meet a child’s evolving nutritional needs, feeding abilities, and developmental progression. However, clinical protocols, product access, and reimbursement vary globally. This study assessed international transition practices.
Methods
A cross-sectional online survey explored health professionals’ practices on transition timing, influencing factors, product forms, casein-glycomacropeptide (cGMP) use, and perceived barriers and facilitators.
Results
A total of 106 professionals from 32 countries participated: Europe (67%), Asia (12%), North America (10%), South America (8%), and Oceania (3%). Dietitians led transitions in 83% of centers. First-stage Phe-free infant formula was typically discontinued at 1–2 years (66%). Second-stage substitutes were introduced at 6–12 months in Europe (61%) and Oceania (100%), but after age one in Asia (69%), North America (72%), and South America (100%). Influencing factors included weaning alignment (46%) and nutritional needs (42%). Semi-solids were preferred in Europe (56%) and Oceania (67%), while powdered drinks dominated in Asia (62%), North America (82%), and South America (100%). Third-stage protein substitutes were introduced at 3–5 years (45%), with later transitions more common in South America (88%) and North America (63%). Ready-to-drink forms were frequent in Oceania (100%), Asia (92%), and Europe (85%). cGMP was prescribed by 61%, mainly guided by preference, Phe tolerance, and adherence; 26% reported no access. Key facilitators for transition included motivation (79%) and sensory properties (69%); barriers included aversion (70%) and poor taste/texture (69%). School involvement was reported by 32%.
Conclusions
Protein substitute transition practices in PKU vary globally. International guidance and equitable product access are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Birmingham Women's and Children's Hospital, Birmingham B4 6NH, UK.
- Department of Nutrition and Dietetics, Ankara Yildirim Beyazit University, Ankara 06760, Turkey.
- Department of Nutrition and Dietetics, Ankara University, Ankara 06290, Turkey.
ORCID-Profile: Sharon Evans, Anne Daly
Zitieren
APA
Yilmaz Nas, O., Ashmore, C., Evans, S., Pinto, A., Daly, A., Yabancı Ayhan, N., & MacDonald, A. (2025). Global Clinical Practice in Transitioning Protein Substitutes for Children with Phenylketonuria. Nutrients. https://doi.org/10.3390/nu17162650
Vancouver
Yilmaz Nas O, Ashmore C, Evans S, Pinto A, Daly A, Yabancı Ayhan N, et al. Global Clinical Practice in Transitioning Protein Substitutes for Children with Phenylketonuria. Nutrients. 2025. doi:10.3390/nu17162650
BibTeX
@article{YilmazNas2025,
author = {Yilmaz Nas, Ozlem and Ashmore, Catherine and Evans, Sharon and Pinto, Alex and Daly, Anne and Yabancı Ayhan, Nurcan and MacDonald, Anita},
title = {Global Clinical Practice in Transitioning Protein Substitutes for Children with Phenylketonuria},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu17162650}
}
EUVIMED